Kuano Ltd raises £275k for quantum simulation drug discovery platform

Developing next-generation medicines through a quantum simulation platform, Kuano Ltd has raised an estimated £275k. The Cambridge-based company combines quantum mechanics and artificial intelligence to design enzyme inhibitors for the pharmaceutical and biotech sectors. These tools are used to create pre-clinical drug candidates for disease targets, specifically focusing on enzymes previously considered undruggable.

Kuano Ltd was incorporated in 2020. The company provides its technology to external partners to accelerate the discovery of new therapeutic leads. The platform aims to provide a more precise method for identifying how enzymes interact with potential drug molecules, overcoming the limitations of traditional drug discovery by simulating molecular interactions at a quantum level. According to its latest financial accounts for the year ended 31 March 2025, the firm employed 12 people.

This latest capital injection (allotted in December 2025) follows two separate funding rounds of £512.9k each in February 2025. Previous funding history includes £865k raised in August 2023 and £469.4k in December 2022. In its earlier stages, the company secured £300k in June 2021, £475k in March 2021, and £150k in March 2020.

The company remains headquartered in Cambridge and continues to target the pharmaceutical and biotech markets, providing candidates for challenging disease targets. This latest round brings the total estimated capital raised by the company since its incorporation to over £3.5m.